• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction

    8/12/25 11:09:00 AM ET
    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Medical Electronics
    Health Care
    Medical Specialities
    Health Care
    Get the next $BFLY alert in real time by email

    USA News Group News Commentary

    Issued on behalf of Avant Technologies Inc.

    VANCOUVER, BC, Aug. 12, 2025 /PRNewswire/ -- USA News Group News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector, with experts both optimistic and horrified at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit nearly $700 billion by 2034, growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval, now one of the biggest hurdles for AI in healthcare is gaining the trust of clinicians and patients alike, all while proving efficacy of these new solutions. From an investment standpoint, the opportunity is enormous, with the market paying closer attention to AI roll outs and the developers behind them, including Avant Technologies, Inc. (OTCQB:AVAI), RadNet, Inc. (NASDAQ:RDNT), Clover Health Investments, Corp. (NASDAQ:CLOV), Tevogen Bio Holdings Inc. (NASDAQ:TVGN), and Butterfly Network, Inc. (NYSE:BFLY).

    USA News Group logo (PRNewsfoto/USA News Group)

    Accenture projects AI could unlock $461 billion in healthcare value by 2035, but success requires platforms that deliver reliable results in critical diagnostics where mistakes prove dangerous. Several innovators are developing advanced systems to capture this opportunity across patient screening and drug discovery.

    Avant Technologies, Inc. (OTCQB:AVAI) and joint-venture partner Ainnova Tech have accelerated their FDA approval timeline for Vision AI, an AI-powered diagnostic tool that can detect diabetic retinopathy in minutes without requiring an eye specialist on-site. The companies have accelerated their timeline by finalizing an enhanced patient recruitment strategy targeting approximately 1,000 multiethnic patients across 8-10 U.S. clinical sites. Ainnova will collaborate directly with Fortrea, a globally recognized contract research organization specializing in ophthalmology studies, to recruit patients primarily from community clinics and primary care facilities. This approach captures real-world data that reflects the diverse population affected by diabetic retinopathy while positioning Vision AI for broader commercial adoption.

    "By focusing on community clinics and targeting a multiethnic group of around 1,000 diabetic patients, we aim to ensure that our study accurately represents the diverse population affected by diabetic retinopathy," said Vinicio Vargas, CEO at Ainnova and Board member of Ai-nova Acquisition Corp. (AAC). "Working with Fortrea, an expert CRO in ophthalmology, allows us to confidently navigate this process with a partner that shares our commitment to quality and efficiency. We are getting closer to initiating a clinical study that will significantly contribute to obtaining FDA 510(k) approval and making our Vision AI platform a crucial tool in early disease detection."

    This recruitment breakthrough builds on decisive regulatory progress following Ainnova's mid-July pre-submission meeting with the FDA, where the agency delivered clear guidance on study design and compliance requirements. The refined clinical trial protocol, which addresses all FDA comments, has been presented to Fortrea for final review and will set the stage for a formal U.S. study that supports FDA 510(k) clearance to market Vision AI domestically.

    Beyond regulatory advancement, Vision AI is gaining commercial momentum across multiple fronts. Vargas recently showcased the platform at Roche's "Macular Spectacular" conference in Colombia, highlighting breakthrough results from a Q4 2024 pilot with Roche and Salud 360 that positions Vision AI for expansion across the U.S., Canada, and Europe.

    The technology has already gone live through Grupo Dökka's Fischel and La Bomba pharmacy chains, delivering walk-in screenings with real-time AI results and eliminating the need for onsite ophthalmologists.

    This proven pharmacy model is attracting attention from insurers and life sciences partners who recognize Vision AI's potential to transform preventive care delivery. The platform's cost-effective approach addresses critical gaps in diabetic eye care while creating new revenue streams for retail healthcare providers.

    Vision AI's success positions Ainnova to dominate broader disease detection markets. The company's expanding roadmap includes cloud-connected retinal cameras for rural clinics and revolutionary modules targeting Alzheimer's, cardiovascular conditions, and other chronic diseases through advanced retinal and blood biomarker analysis.

    With diabetic retinopathy affecting 9.6 million Americans and representing a US$3.25 billion U.S. market projected to nearly double to US$6.1 billion by 2033, Avant maintains worldwide licensing rights to Ainnova's platform through AAC. This positions U.S. market entry as a transformative commercial inflection point.

    Avant continues evaluating a strategic acquisition of Ainnova Tech under a previously announced non-binding LOI, potentially consolidating breakthrough AI healthcare technologies and proven leadership under a single public platform. The company has also signaled plans for a dedicated therapeutic-focused spinout, creating multiple pathways to capture the expanding AI-driven healthcare transformation.

    CONTINUED… Read this and more news for Avant Technologies Inc. https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    RadNet, Inc. (NASDAQ:RDNT), through its wholly-owned subsidiary DeepHealth Inc., received FDA 510(k) clearance for TechLive™, a remote scanning solution that enables centralized operation of MR, CT, PET/CT, and ultrasound procedures across multiple locations simultaneously. The technology addresses critical radiology technologist shortages by allowing expert staff to remotely guide complex procedures, with pilot deployments showing a 42% decrease in MRI room closure hours.

    "TechLive™ represents a paradigm shift in how we approach imaging operations," said Sham Sokka, PhD, Chief Operating and Technology Officer at DeepHealth. "By enabling real-time remote expertise, we are not only addressing today's staffing challenges, we are creating a foundation for more efficient, financially sustainable, and high-quality patient care across the broadest set of imaging modalities. This FDA clearance validates DeepHealth's vision of a connected imaging ecosystem that scales human expertise beyond physical boundaries."

    RadNet has already connected over 300 imaging systems with TechLive™, positioning the company to expand operational efficiency while improving patient access to advanced diagnostic procedures.

    Clover Health Investments, Corp. (NASDAQ:CLOV), through its wholly-owned subsidiary Counterpart Health, released clinical data showing its AI-powered Counterpart Assistant technology correlates with significantly improved COPD patient outcomes, including 15% fewer hospitalizations and 18% lower 30-day readmissions.

    "This whitepaper shows how translating raw data into real-time clinical insight can transform care," said Conrad Wai, CEO of Counterpart Health. "By equipping physicians with timely, meaningful guidance, Counterpart Assistant helps deliver better outcomes for patients and reduce costs."

    The platform synthesizes over 100 real-time data streams to provide actionable recommendations within clinical workflows, with COPD patients under Counterpart-enabled primary care physicians showing 75% higher diagnosis rates and 18% more specialty care visits. This marks Counterpart's fifth published study demonstrating clinical impact across chronic diseases including diabetes, heart failure, and kidney disease management.

    Tevogen Bio Holdings Inc. (NASDAQ:TVGN) has evolved from a biotechnology company into a dual-platform enterprise expanding into artificial intelligence through Tevogen.AI while maintaining 74% insider ownership. The company successfully launched its AI-driven PredicTcell™ platform with strategic partnerships including Microsoft and Databricks, significantly enhancing drug target discovery efficiency with potential savings of billions in development costs.

    CEO Ryan Saadi affirmed the company's strong capital position and growth trajectory, highlighting progress from clinical validation of its ExacTcell™ platform to establishing manufacturing capabilities and robust intellectual property portfolios.

    "Tevogen has become a recognized name for its business philosophy of social responsibility, patient affordability and cost efficiency," wrote Saadi in a CEO letter. "In under five years, we validated our proprietary ExacTcell™ platform, completed successful proof-of-concept clinical trial of the platforms first product, established drug discovery R&D center — currently in the process of establishing our own GMP cell manufacturing facility, expanded corporate infrastructure, built a robust intellectual property portfolio, and established one of the pioneering AI initiatives in the industry — assets of significant value, while maintaining 74% insider equity ownership."

    Butterfly Network, Inc. (NYSE:BFLY) advanced AI-powered cardiac screening through new research demonstrating machine learning models can achieve 94% accuracy in detecting aortic stenosis using handheld ultrasound devices.

    "This research shows a promising path forward where lower-level providers, not just cardiologists or trained sonographers, could screen for aortic stenosis using AI-assisted handheld ultrasound," said Dr. John Martin, co-author of the study and Butterfly's Chief Medical Officer Emeritus. "This opens the door to early detection in a wide variety of care venues including primary care offices, long term care facilities, urgent care facilities and even in the home."

    The study, published in European Heart Journal, validates the potential for lower-level providers to screen for this life-threatening condition that affects over 13% of Americans over 75 and often goes undiagnosed until advanced stages. Butterfly also released new Aorta Exam training protocols on its ScanLab™ platform, combining AI-assisted diagnostics with educational tools to democratize access to critical cardiovascular screening capabilities.

    Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

    CONTACT:

    USA NEWS GROUP

    [email protected]

    (604) 265-2873

    DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Logo - https://mma.prnewswire.com/media/2603685/5456585/USA_News_Group_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/healthcare-ai-market-explodes-38-5-annually-as-diagnostics-gain-fda-traction-302527904.html

    SOURCE USA News Group

    Get the next $BFLY alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BFLY
    $CLOV
    $RDNT
    $TVGN

    CompanyDatePrice TargetRatingAnalyst
    Butterfly Network Inc.
    $BFLY
    8/1/2025Outperform → Perform
    Oppenheimer
    Butterfly Network Inc.
    $BFLY
    7/1/2025$3.00Buy
    Craig Hallum
    RadNet Inc.
    $RDNT
    6/13/2025$69.00Buy
    B. Riley Securities
    Butterfly Network Inc.
    $BFLY
    3/17/2025Outperform
    William Blair
    RadNet Inc.
    $RDNT
    3/5/2025$85.00 → $65.00Outperform → Strong Buy
    Raymond James
    Tevogen Bio Holdings Inc.
    $TVGN
    3/4/2025$10.00Buy
    D. Boral Capital
    Clover Health Investments Corp.
    $CLOV
    12/17/2024$6.00Buy
    Craig Hallum
    Clover Health Investments Corp.
    $CLOV
    10/7/2024$4.00Neutral
    UBS
    More analyst ratings

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    SEC Filings

    View All

    SEC Form 424B3 filed by Tevogen Bio Holdings Inc.

    424B3 - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    9/26/25 5:18:10 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Tevogen Bio Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Tevogen Bio Holdings Inc. (0001860871) (Filer)

    9/26/25 5:15:56 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by RadNet Inc.

    144 - RadNet, Inc. (0000790526) (Subject)

    9/10/25 6:29:31 PM ET
    $RDNT
    Medical Specialities
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RadNet, Inc. to Present at the Jefferies Healthcare Services Conference on September 29, 2025

    LOS ANGELES, Sept. 26, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, and Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the Jefferies Healthcare Services Conference on Monday, September 29, 2025 at 1:50 p.m. Central Time (11:50 a.m. Pacific Time). There will be simultaneous and archived webcasts available at https://wsw.com/webcast/jeff329/rdnt/1868632 and www.radnet.com under the "About RadNet

    9/26/25 6:00:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion

    Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision immunotherapy development and efficacy through advanced machine learning and transformer-based models. The platform is being developed with the support of Microsoft (NASDAQ: MSFT) and Datab

    9/25/25 8:30:00 AM ET
    $MSFT
    $TVGN
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Counterpart Assistant Gets Conversational

    SAN FRANCISCO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) ("Clover," "Clover Health" or the "Company") and a leading AI‑powered physician‑enablement platform, today announced the next step in the evolution of its flagship Counterpart Assistant (CA): generative AI capabilities that let clinicians engage with a patient's longitudinal data in real time through AI chat. Instead of digging through countless clinical documents when researching patients, clinicians can now ask questions about a patient's medical history in natural language within a protected health information (PHI)-safe

    9/25/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Butterfly Network downgraded by Oppenheimer

    Oppenheimer downgraded Butterfly Network from Outperform to Perform

    8/1/25 12:44:19 PM ET
    $BFLY
    Medical Electronics
    Health Care

    Craig Hallum initiated coverage on Butterfly Network with a new price target

    Craig Hallum initiated coverage of Butterfly Network with a rating of Buy and set a new price target of $3.00

    7/1/25 8:24:04 AM ET
    $BFLY
    Medical Electronics
    Health Care

    B. Riley Securities initiated coverage on RadNet with a new price target

    B. Riley Securities initiated coverage of RadNet with a rating of Buy and set a new price target of $69.00

    6/13/25 7:50:00 AM ET
    $RDNT
    Medical Specialities
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Toy Andrew covered exercise/tax liability with 308,950 shares, decreasing direct ownership by 3% to 10,165,562 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    10/3/25 4:10:15 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Chief Technology Officer Ku Victor was granted 847,930 shares (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    9/24/25 4:09:25 PM ET
    $BFLY
    Medical Electronics
    Health Care

    SEC Form 3 filed by new insider Ku Victor

    3 - Butterfly Network, Inc. (0001804176) (Issuer)

    9/24/25 4:07:50 PM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Business Officer Cashman Steve bought $81,953 worth of shares (50,000 units at $1.64), increasing direct ownership by 2% to 2,324,474 units (SEC Form 4)

    4 - Butterfly Network, Inc. (0001804176) (Issuer)

    8/27/25 8:56:48 AM ET
    $BFLY
    Medical Electronics
    Health Care

    Director Loengard Anna U bought $68,755 worth of shares (26,500 units at $2.59) (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/14/25 4:44:26 PM ET
    $CLOV
    Medical Specialities
    Health Care

    Director Garipalli Vivek bought $998,997 worth of shares (446,980 units at $2.23), increasing direct ownership by 32% to 1,856,247 units (SEC Form 4)

    4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

    8/8/25 4:07:07 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Leadership Updates

    Live Leadership Updates

    View All

    Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

    WILMINGTON, Del., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company dedicated to bringing access to great healthcare to everyone on Medicare, today celebrates the appointment of Dr. Ian Duncan, Ph.D., FSA, FIA, FCIA, FCA, CSPA MAAA, a member of Clover's Medicare Advantage Board of Directors, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries (SOA). On September 12, 2025, the SOA announced that Dr. Duncan will become the 78th President and Chair at the 2026 SOA ImpACT Annual Conference. With roots dating back to 1889, the SOA is the world's largest actuarial

    9/18/25 8:30:00 AM ET
    $CLOV
    Medical Specialities
    Health Care

    Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston

    WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen ("Tevogen Bio Holdings Inc." or "Company") (NASDAQ:TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry peers including Chris Gervais, CTO of Codametrix, and Stavros Papadopoulos, CEO of TileDB, in a discussion moderated by Tony Pezzullo, Principal at SignalFire. Mehta will share perspectives on Te

    9/10/25 11:59:02 AM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Butterfly Network Appoints Victor Ku as Chief Technology Officer

    Butterfly Network, Inc. (NYSE:BFLY), a digital health company transforming care through portable, semiconductor-based ultrasound technology and intuitive software, today announced the appointment of Victor Ku as Senior Vice President and Chief Technology Officer (CTO). Victor will join the company in late September and will be responsible for leading Butterfly's global technology strategy, product development, and innovation roadmap. "Victor's deep expertise in semiconductor-based imaging and his proven ability to scale global product development make him a perfect fit for Butterfly's next phase of growth," said Joseph DeVivo, President and CEO of Butterfly Network. "His leadership will b

    9/9/25 8:00:00 AM ET
    $BFLY
    Medical Electronics
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Financials

    Live finance-specific insights

    View All

    Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum

    Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. ("Tevogen" or the "Company) (NASDAQ:TVGN) announced its financial results for the fiscal quarter ended June 30, 2025, and filed its Form 10-Q with the Securities and Exchange Commission ("SEC

    8/19/25 12:10:00 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    RadNet Reports Second Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges

    Total Company Revenue increased 8.4% to a quarterly record of $498.2 million in the second quarter of 2025 from $459.7 million in the second quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 30.9% to a quarterly record of $20.7 million in the second quarter of 2025 from $15.8 million in the second quarter of 2024Total Company Adjusted EBITDA(1) was a quarterly record of $81.2 million in the second quarter of 2025 as compared with $72.3 million in the second quarter of 2024, an increase of 12.3%; Digital Health reportable segment Adjusted EBITDA(1) increased 4.1% to $3.4 million in the second quarter of 2025 from $3.3 million in

    8/10/25 4:00:00 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Clover Health Reports Second Quarter 2025 Results; Delivering Strong Sustainable Growth

    Second quarter 2025 Medicare Advantage membership of 106,323, up 32% year-over-yearSecond quarter 2025 Total revenues of $478 million, up 34% year-over-yearSecond quarter 2025 profitability metrics with GAAP Net loss of $11 million, Adjusted EBITDA of $17 million, and Adjusted Net income of $17 million Updates Full Year 2025 Guidance: Increases Average Medicare Advantage membership to 104,000 - 108,000, representing 32% growth year-over-year at the midpointMaintains Insurance revenue between $1.800 billion and $1.875 billion, representing 37% growth year-over-year at the midpointImproves Adjusted SG&A to between $335 million and $345 million, representing Adjusted SG&A as a percentage

    8/5/25 4:05:00 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Financial Insight: Purchase at Clover Health Investments Corp. on Jun 20

    The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

    6/20/24 6:36:05 PM ET
    $CLOV
    Medical Specialities
    Health Care

    $BFLY
    $CLOV
    $RDNT
    $TVGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/14/24 5:29:01 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by RadNet Inc.

    SC 13G/A - RadNet, Inc. (0000790526) (Subject)

    11/12/24 4:51:53 PM ET
    $RDNT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tevogen Bio Holdings Inc.

    SC 13G/A - Tevogen Bio Holdings Inc. (0001860871) (Subject)

    11/12/24 4:28:55 PM ET
    $TVGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care